Balyasny Asset Management’s Cogent Biosciences COGT Stock Holding History
Bought
Maintained
Sold
Other funds holding COGT
Balyasny Asset Management's COGT Position: Q3 2026 in Review
Balyasny Asset Management reduced its Cogent Biosciences (COGT) stake by 15% in Q3 2026, selling an estimated $5.23M and leaving 813,281 shares worth $26M. The position accounts for 0.03% of the portfolio, ranked #640.
Balyasny Asset Management first reported a position in COGT in Q2 2022 and has held it in 13 quarters since. The position peaked at $51.2M in Q4 2025. 316 funds tracked by Wall St. Rank hold COGT as of Q3 2026.
- Balyasny Asset Management held 813,281 shares of Cogent Biosciences worth $26M as of Q3 2026.
- Balyasny Asset Management sold 141,562 Cogent Biosciences shares in Q3 2026, an estimated $5.23M.
- Cogent Biosciences made up 0.03% of Balyasny Asset Management's portfolio in Q3 2026, its #640 holding.
- Balyasny Asset Management first reported a position in Cogent Biosciences in Q2 2022 and has held it in 13 quarters since.
- Balyasny Asset Management's Cogent Biosciences position peaked at $51.2M in Q4 2025.
- 316 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2026.
Based on Balyasny Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.